Clicky

Recordati Industria Chimica e Farmaceutica S.p.A.(RICFY)

Description: Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. It operates through Specialty and Primary Care and Rare Diseases segments. The company's product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS for the treatment of cystine crystal deposits in the cornea. It also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma; and FOTIVDA, an oral inhibitor first-line treatment of renal cell carcinoma. In addition, the company offers SYLVANT for the treatment of idiopathic multicentric castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment electrolyte supersaturated of oral mucositis due to chemo and radiation therapy. Recordati Industria Chimica e Farmaceutica S.p.A. was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. is a subsidiary of Rossini S.à R.L.


Keywords: Pharmaceutical Radiation Chemotherapy Rare Diseases Transplantation Radiation Therapy Schizophrenia Brain Tumor Renal Cell Carcinoma Neuroblastoma Hematopoietic Stem Cell Transplantation Oral Mucositis Mucositis Caphosol Eligard Endogenous Cushing's Syndrome High Risk Neuroblastoma

Home Page: www.recordati.com

Via Matteo Civitali,1
Milan, MI 20148
Italy
Phone: 39 02 487871


Officers

Name Title
Dr. Robert Koremans M.D. CEO & Director
Mr. Luigi Felice La Corte Group CFO & Executive Director
Ms. Cathrin Petty Executive Director
Mr. Giampiero Mazza Executive Director
Mr. Giorgio De Palma Executive Director
Ms. Eugenia Litz VP & Head of Investor Relations
Ms. Bibianne Bon Group Chief Legal Officer
Ms. Laura Conti Group Communications Director
Mr. Gabriele Finzi Executive VP of Corporate Development, Licensing & Innovation
Ms. Alessandra Abate Group Chief People & Culture Officer

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 16.2866
Trailing PE: 25.2547
Price-to-Book MRQ: 5.6072
Price-to-Sales TTM: 4.903
IPO Date:
Fiscal Year End: December
Full Time Employees: 4450
Back to stocks